Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
2(28.6%)
Early Phase 1
1(14.3%)
7Total
Phase 1(4)
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05664100Phase 1Terminated

First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss

Role: lead

NCT04120116Phase 2Completed

FX-322 in Adults With Stable Sensorineural Hearing Loss

Role: lead

NCT05086276Phase 2Completed

FX-322 in Adults With Acquired Sensorineural Hearing Loss

Role: lead

NCT03616223Phase 1Completed

FX-322 in Sensorineural Hearing Loss

Role: lead

NCT04601909Phase 1Completed

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

Role: lead

NCT04629664Phase 1Completed

FX-322 in Adults With Severe Sensorineural Hearing Loss

Role: lead

NCT03300687Early Phase 1Completed

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

Role: lead

All 7 trials loaded